Literature DB >> 24913929

Inadvertent subclavian artery cannulation treated by percutaneous closure.

José E Cohen1, J Moshe Gomori2, Haim Anner3, Eyal Itshayek4.   

Abstract

Accidental arterial puncture occurs in around 1% and 2.7% of jugular and subclavian approaches, respectively. When a line has been inadvertently inserted into an artery at a noncompressible site, there is an increased risk for serious complications. This complication can be treated by either surgical or endovascular intervention or a combination; however, in critically ill patients or in those with impaired coagulation, therapeutic options are more limited. We describe successful endovascular management of inadvertent subclavian artery cannulation during insertion of a triple lumen central line catheter in a 35-year-old man suffering from leukemia, with sepsis and multi-organ failure. He was hypotensive and hemodynamically unstable, with severe coagulopathy. The catheter had entered the artery at the level of the origin of the internal mammary artery, just above the origin of the vertebral artery. The tip was lying in the aortic arch. The artery was successfully closed by endovascular deployment of an 8 French Angio-Seal device (St. Jude Medical, St. Paul, MN, USA). The device is licensed for use in femoral arterial puncture sites but provided safe and effective closure of the subclavian artery puncture in our patient.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hemorrhage; Iatrogenic cannulation; Stent graft; Subclavian artery; Vascular closure device

Mesh:

Year:  2014        PMID: 24913929     DOI: 10.1016/j.jocn.2014.04.009

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  1 in total

Review 1.  Closure Devices for Iatrogenic Thoraco-Cervical Vascular Injuries.

Authors:  Gregory C Makris; Rafiuddin Patel; Mark Little; Carina Tyrrell; James Sutcliffe; Kader Allouni; Mark Bratby; Susan Anthony; Raman Uberoi
Journal:  Cardiovasc Intervent Radiol       Date:  2016-11-28       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.